Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)

Eur J Clin Pharmacol. 2009 Jan;65(1):1-2. doi: 10.1007/s00228-008-0571-x. Epub 2008 Oct 29.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cytochrome P-450 CYP2C19
  • Down-Regulation
  • Drug Administration Schedule
  • Gastric Acid / metabolism*
  • Gastric Acidity Determination
  • Gastroesophageal Reflux / drug therapy*
  • Gastroesophageal Reflux / enzymology
  • Gastroesophageal Reflux / genetics
  • Gene Frequency
  • Heterozygote
  • Homozygote
  • Humans
  • Omeprazole / administration & dosage
  • Omeprazole / pharmacokinetics
  • Phenotype
  • Polymorphism, Genetic*
  • Proton Pump Inhibitors / administration & dosage*
  • Proton Pump Inhibitors / blood
  • Proton Pump Inhibitors / pharmacokinetics*
  • Treatment Outcome

Substances

  • Proton Pump Inhibitors
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Omeprazole